- Home
- IBCP vs KURA Comparison
IBCP vs KURA Comparison
Compare IBCP & KURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IBCP
- KURA
- Stock Information
- Founded
- IBCP 1864
- KURA 2014
- Country
- IBCP United States
- KURA United States
- Employees
- IBCP N/A
- KURA N/A
- Industry
- IBCP Major Banks
- KURA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- IBCP Finance
- KURA Health Care
- Exchange
- IBCP Nasdaq
- KURA Nasdaq
- Market Cap
- IBCP 791.0M
- KURA 793.2M
- IPO Year
- IBCP N/A
- KURA N/A
- Fundamental
- Price
- IBCP $37.77
- KURA $9.50
- Analyst Decision
- IBCP Hold
- KURA Strong Buy
- Analyst Count
- IBCP 3
- KURA 10
- Target Price
- IBCP $34.83
- KURA $30.13
- AVG Volume (30 Days)
- IBCP 62.9K
- KURA 2.9M
- Earning Date
- IBCP 01-23-2025
- KURA 11-07-2024
- Dividend Yield
- IBCP 2.58%
- KURA N/A
- EPS Growth
- IBCP 3.52
- KURA N/A
- EPS
- IBCP 2.94
- KURA N/A
- Revenue
- IBCP $208,212,000.00
- KURA N/A
- Revenue This Year
- IBCP N/A
- KURA N/A
- Revenue Next Year
- IBCP $5.96
- KURA $106.66
- P/E Ratio
- IBCP $12.65
- KURA N/A
- Revenue Growth
- IBCP 3.25
- KURA N/A
- 52 Week Low
- IBCP $22.53
- KURA $9.40
- 52 Week High
- IBCP $40.32
- KURA $24.17
- Technical
- Relative Strength Index (RSI)
- IBCP 53.83
- KURA 24.01
- Support Level
- IBCP $36.95
- KURA $9.40
- Resistance Level
- IBCP $38.30
- KURA $10.02
- Average True Range (ATR)
- IBCP 0.95
- KURA 0.46
- MACD
- IBCP -0.18
- KURA 0.10
- Stochastic Oscillator
- IBCP 47.89
- KURA 8.09
About IBCP Independent Bank Corporation
Independent Bank Corp (Ionia MI) operates as a commercial bank. It offers a broad range of banking services to individuals and businesses, including checking and savings accounts, commercial lending, direct and indirect consumer financing, mortgage lending, and safe deposit box services. It also provides internet and mobile banking capabilities to its customers.
About KURA Kura Oncology Inc.
Kura Oncology Inc is a clinical-stage biopharmaceutical company, that engages in discovering and developing therapeutics for the treatment of solid tumors and blood cancers. It focuses on the development of small-molecule product candidates that target cell signaling pathways to drive the progression of various cancers. The company has a product candidate, Tipifarnib, which is a farnesyl transferase inhibitor, in both solid tumors and blood cancers. Geographically operation of the group is carried through the United States.